Orbital Therapeutics Funding: $270M Raised, Series A (2023)

Orbital Therapeutics is based in Cambridge. It has raised $270M in total funding. Latest round: Series A.

Orbital Therapeutics funding overview

Orbital Therapeutics is based in Cambridge. Orbital Therapeutics has raised $270M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series A announced in April 2023. The round record for Orbital Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Arch Venture Partners, a16z Bio + Health, Newpath Partners. 3 distinct backers are named across the disclosed rounds.

Orbital Therapeutics at a glance

Total raised
$270M
Latest round
Series A
Latest round date
April 2023
Headquarters
Cambridge
Notable investors
Arch Venture Partners, a16z Bio + Health, Newpath Partners

Frequently asked about Orbital Therapeutics funding

How much has Orbital Therapeutics raised?
Orbital Therapeutics has raised $270M in total disclosed funding across the rounds on record.
Who has invested in Orbital Therapeutics?
Arch Venture Partners, a16z Bio + Health, Newpath Partners are named among the investors backing Orbital Therapeutics.
What was the latest Orbital Therapeutics funding round?
The most recent disclosed round is a Series A, announced in April 2023.
Where is Orbital Therapeutics based?
Orbital Therapeutics is based in Cambridge.
When did Orbital Therapeutics last raise?
The last disclosed Orbital Therapeutics round closed in April 2023 at Series A.

Round data for Orbital Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Cambridge and backer lists below.

Orbital Therapeutics funding history

1 disclosed round on record.

  1. April 2023 — Series A. $270M.

Companies related to Orbital Therapeutics (31)

Browse related funding lists (7)

Company funding database · Investor directory · Founder database · Mega-rounds 2026